//@version=5 strategy("Tesla Bot", overlay=true, default_qty_type=strategy.percent_of_equity, default_qty_value=10) // اندیکاتور میانگین متحرک ساده برای سیگنال خرید و فروش shortMa = ta.sma(close, 9) longMa = ta.sma(close, 21) // سیگنال خرید و فروش buySignal = ta.crossover(shortMa, longMa) sellSignal = ta.crossunder(shortMa, longMa) // نمایش سیگنال روی چارت plotshape(series=buySignal, location=location.belowbar, color=color.green, style=shape.labelup, title="BUY") plotshape(series=sellSignal, location=location.abovebar, color=color.red, style=shape.labeldown, title="SELL") // اجرای سفارشات strategy.entry("Buy", strategy.long, when=buySignal) strategy.close("Buy", when=sellSignal)
If the bearish support breaks the other support, the NR will be negative on the RSI indicator
Across the US, there is a pent-up demand for housing (for the vast majority of locations). While the media likes to selectively report home sales dropping for certain regions, it is more due to mortgage rates and seasonality than demand. Mortgage rates are anticipated to come down over the next 1-2 years and home builders will step in to pick-up the lack of inventory. Healthy companies like Lennar Corp NYSE:LEN , with a P/E of 8x, dividend of 1.68%, very low debt-to-equity (0.17x), etc are likely to prosper, but always stay cautious with the dreaded "recession" announcement if it creeps in... Thus, at $116.48, NYSE:LEN is in a personal buy-zone. In the near-term, I do see the potential for the price to dip near $100 as tariff and other economic red flags continue to be in focus. Targets: $131.00 $145.00 $157.00 $180.00
In the current gold market, the downward trend is more obvious. However, it is noteworthy that gold has tested the key point of 3000 many times, and each time it breaks through, it is unstable. This fully shows that the defense above the 2995-2990 support area is extremely strong and difficult to be effectively broken in the short term. Combined with the downward momentum observed in the 3000 point range, although it is in a downward trend, the possibility of a sharp decline is extremely small. Judging from the comprehensive judgment of technical analysis and market sentiment, gold will not only not continue to fall, but will most likely rebound. It is initially estimated that the rebound target will reach the area around 3015, and it is very likely to extend further to the area around 3025-3035. Let us look forward to the performance of gold together! The content I shared recently about the gold market has received a lot of feedback, and everyone said it was very helpful!If you don’t know when to enter the market, you can follow me ?, I will release specific signals in real time, and remember to pay attention to the bottom ? signal in time.
On Monday, the price of gold exhibited relatively subdued behavior, largely oscillating within a narrow trading band. During the European trading session, the yellow metal briefly ascended to test the $3,033 resistance level. Subsequently, in the US trading session, it encountered a significant pullback, with prices temporarily dipping to a low of $3,002. Despite the emergence of a rebound, the momentum behind it appears lackluster. Looking ahead, in the subsequent trading, gold is anticipated to consolidate within the range of $3,000 - $3,030. XAUUSD sell@3025-3035 tp:3010 buy@3000-3010 tp:3030 I will share trading signals every day. All the signals have been accurate for a whole month in a row. If you also need them, please click on the link below the article to obtain them.
Bitcoin (BTCUSD) is trading inside a rising wedge pattern on the 4H chart—typically a bearish reversal structure. Price is currently hovering near the wedge resistance and a previous supply zone, presenting a clean short opportunity with solid risk-to-reward. ? Technical Breakdown 1. Rising Wedge Formation The price action has formed a clear rising wedge, a pattern often associated with a bearish breakout. Current price action shows momentum fading near the wedge top, aligning with historical resistance. 2. Key Sell Zone The 88,600–89,000 region marks an ideal short-entry zone. This overlaps with a prior consolidation/supply block and wedge resistance—making it a high confluence zone. 3. Bearish Target & Projection Breakdown of wedge support could drive price down toward the target zone near 78,000, a potential -8.89% move. This target zone acted as a strong demand area in mid-March and is likely to attract buy interest again. ? Trade Plan Sell Entry: Around 88,600–89,000 Stop Loss: Above 92,923 (beyond wedge + supply zone) Target: 78,000 zone, prior demand and technical projection Risk-to-Reward: High conviction R:R setup with structured invalidation ⚠️ Watch for Confirmation Ideal confirmation would be a strong bearish 4H candle below wedge support or bearish divergence on RSI/MACD.
After a great recovery from 47,884 levels till 51700 in 2 weeks, a posible short from the current or 51760 , 51860, 51900 can be placed otherwise ride the markets & see the portfolios in good weekly gains first time in 2025
Why I Proposed to NASDAQ:ANNX today? When will we get married? We all know the golden rule of trading penny stocks keep emotions out of it. Let logic dictate your moves, and don’t overdo the due diligence, because today’s small-cap darling can be tomorrow’s micro-cap disaster. But today, I took a big chunk of my gains from a penny stock account and decided to put a ring on $ANNX. This stock is like a tiny wildflower in a crowded field easy to overlook until you get up close with a magnifying glass. Let’s skip the poetry and get straight to the facts: 1. ANX005 – The Dark Horse in Neuromuscular Treatment ANX005 is a strong contender in the treatment of Guillain-Barré Syndrome (GBS) and muscle atrophy. The drug has shown better-than-expected results in Phase 3 trials, which is huge. Institutional investors and major banks seem to have caught the scent of a potential commercial breakthrough, given how far ANX005 has progressed toward FDA approval. 2. ANX007 – A Potential Game-Changer for Vision Loss The FDA has greenlit Phase 3 trials for ANX007, aimed at treating Geographic Atrophy (GA), a severe form of retinal degeneration. While final results are still pending, ANX007 is one of the few treatments at this advanced stage that protects and enhances vision without needing to shrink lesions. If it clears this hurdle, this could be a massive win in ophthalmology. 3. Cash Reserves > Market Cap – A Financial Fortress Here’s where things get really interesting ANNX’s total cash reserves exceed its market cap. With only $44M in R&D costs and $9M in operational expenses, ANNX stands out among biotech penny stocks, most of which burn through cash and constantly dilute shares just to survive. Unlike them, ANNX has enough runway to last at least 8 more quarters without raising additional capital. That means no dilution risk for the next two years a rare luxury in this space. 4. Smart Clinical Trials Strategy ANNX has prioritized international trials outside the U.S., particularly in Southwest and Southeast Asia, where costs are lower and patient enrollment is faster. While some skeptics may question data transparency, the strategy accelerates timelines and saves money. The FDA still approved ANX005 and ANX007 for their final stages, which speaks volumes about the trial results. 5. Commercial Potential – $600M Market Opportunity The U.S. market alone could support 5,000 patients annually, translating to a potential $600M revenue stream per year. This doesn’t even factor in international markets. Price Targets and Institutional Sentiment Despite ANNX’s strong fundamentals, risks remain biotech investing is never smooth sailing. That said, I’m rating NASDAQ:ANNX a Moderate Buy and holding for at least 3 months, expecting a run to $4.00 –$6.00 by Q3 2025 and potentially $7.50 - 10.00 during Christmas 2025. Meanwhile, big players like: Wells Fargo, JP Morgan, and Bank of America almost have the same consensus target of $14. Needham says $16, HC Wainwright is going full send with $20. Total 7 Strong Buy, 0 Hold or Sell. Bonus Tip: Follow the Options Flow Take a peek at NASDAQ:ANNX ’s options chain. The big dogs have been scooping up ITM and ATM call options aggressively a classic sign that they’re loading up for a serious move in the next six months. If you’re worried about macro risks like tariffs, economic slowdowns, or financial crises, hidden gems in biotech might just be a solid "cave". Beware short sellers, there are always sharks in the Pennystocks forums waiting for posts like this to trigger their greed. But, I bought the share by profit, target to long term, I don't mind the Daily chart, just look at Weekly and Monthly charts. Ready to DCA when ANNX drop to $1.00. Just cut loss whenever the really Bad-news is real and confirmed. Here’s hoping my wedding day arrives when NASDAQ:ANNX hits $10.00. (Disclaimer: ChatGPT helped me research and write this article, as Biotech is not my primary field. This is just my personal analysis. Not financial advice at all. Trade responsibly.)
#btc could be heading to 110k if we hold support it looks promising
Right now, is probably a good moment to open short positions. The price reached the level I was pointing to, just perfectly! It's incredible how accurately rules, norms and relationships are working. I am amazed every time when see in action the power of the principle. Hope you were in time to open short positions. My base scenario - I am anticipating Dogecoin at 0.118 - 0.085 USD now and well bounce after this. Be careful, we will have the reverse confirmations upon usdt.d consolidates above 5.20%. Consolidation below 5% will indicate a massive uptrend continuation. PS: one more important observation is - I had my doubts whether price could go out of trend, within 2 & 4 waves. Within this formation we see a strong test, but not a break (as of now). This shows that a simple forecasting tools are one of the most reliable.